The Economic Times Healthcare and Biotech News This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Biocon weighs sale of $1.5 billion generic API business
The Kiran Mazumdar-Shaw helmed company made a huge bet on biosimilars by acquiring a portfolio of drugs from global drug major Viatris for $3.34 billion in November last year. That deal was funded by debt taken both by Biocon Ltd and its biosimilars arm Biocon Biologics. Biocon Biologics took loans of $1.2 billion to fund the acquisition. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - December 15, 2023 Category: Pharmaceuticals Source Type: news

CDSCO uncovers data manipulation, SOP violations by public testing labs
The Central Drugs Standard Control Organisation (CDSCO), along with state drug inspectors, have been doing these inspections as part of a massive nationwide crackdown on spurious and substandard medicines. At present Phase IV of risk based inspections (RBI) is ongoing. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - December 14, 2023 Category: Pharmaceuticals Source Type: news

Multiples PE-backed Zenex acquires Dabur promoter Pradeep Burman's Ayurvet
Ayurvet, founded as a subsidiary of Dabur India in 1992 and later spun off as an independent entity in 2002, is a leading provider of ayurvedic and herbal medicines, feed supplements and topical treatments for farm and companion animals. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - December 14, 2023 Category: Pharmaceuticals Source Type: news

Zydus Lifesciences gets USFDA nod for generic cancer treatment capsules
Zydus Lifesciences Ltd has received final approval from the USFDA for its generic version of the cancer treatment drug Cyclophosphamide capsules. The approval covers strengths of 25 mg and 50 mg. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - December 14, 2023 Category: Pharmaceuticals Source Type: news

Sun Pharma specialty drug Tildrakizumab makes it to China's reimbursement list
The inclusion of tildrakizumab injection in NRDL will further boost Sun Pharma commercialisation efforts globally. NRDL is a list of drugs fully or partially reimbursed by the national basic health insurance in China covering 96% of the population or more than 1.36 billion people. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - December 13, 2023 Category: Pharmaceuticals Source Type: news

Drug launches, new permissions should be made public, say pharma MNCs
In a recent meeting held by the drug controller on global clinical trials, the OPPI sought from the government a notification system through the drug regulatory authority's digital portal-SUGAM. It has asked for linking of the SUGAM Portal at Centre and state levels and, then, making public the non-commercial information in respect of the filed/pending applications and the approvals granted, it said. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - December 12, 2023 Category: Pharmaceuticals Source Type: news

Meftal maker says adverse reaction flagged by IPC is very rare
Blue Cross Laboratories, the owner of the Meftal painkiller brand, has clarified that the adverse reaction the Indian Pharmacopoeia Commission (IPC) has flagged is a rare event. The company claims that the product's constituent, mefenamic acid, can cause adverse reactions, including eosinophilia and systemic symptoms (DRESS) syndrome. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - December 12, 2023 Category: Pharmaceuticals Source Type: news

Reports claiming non-procurement of contraceptives misleading: Govt
The Central Medical Services Society (CMSS), an autonomous body and a Central Procurement Agency under Union Ministry of Health, procures condoms for National Family Planning Programme and National AIDS Control Programme. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - December 12, 2023 Category: Pharmaceuticals Source Type: news

Sun Pharma revises upwards price to fully acquire Taro to USD 43 per share
In May this year, Sun Pharmaceutical Industries announced a non-binding indication of interest to acquire all of the outstanding ordinary shares of Taro for a purchase price of USD 38 per ordinary share in cash through a reverse triangular merger. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - December 12, 2023 Category: Pharmaceuticals Source Type: news

USFDA issues Form 483 with 5 procedural observations to Torrent Pharma's Gujarat unit
Torrent Pharmaceuticals said Tuesday that the US health regulator has given them a Form 483 with five procedural comments after inspecting their oral manufacturing facility in Gujarat, India. According to the US Food and Drug Administration (USFDA), Form 483 is given to a company's management after an inspection if the investigator notices any conditions that might break the rules under the Food Drug and Cosmetic (FD&C) Act and related Acts. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - December 12, 2023 Category: Pharmaceuticals Source Type: news

Cipla unit recalls one lot of medication in US due to seal integrity issue
Drug major Cipla's subsidiary is voluntarily recalling one lot of medication in the US due to seal integrity issues. InvaGen Pharmaceuticals Inc, USA, is voluntarily recalling one lot of Vigabatrin for Oral Solution, USP (500 mg), at the consumer level due to seal integrity issues, allowing for powder leakage from the pouch, the Mumbai-based drug maker said in a regulatory filing. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - December 10, 2023 Category: Pharmaceuticals Source Type: news

USFDA pulls up Intas Pharma for manufacturing lapses at Ahmedabad plant
In a warning letter to the company's CEO and MD Nimish Chudgar, the US Food and Drug Administration (USFDA) has pointed out various manufacturing lapses at the Matoda-Sanand, Ahmedabad-based facility. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - December 10, 2023 Category: Pharmaceuticals Source Type: news

Masks are still being worn by some individuals—but not for health reasons
A remnant of the Covid-19 era, masks are being worn by some individuals not only for health reasons but also for the sake of privacy. The demand for masks has dropped significantly after Covid. A Statista Consumer Market Insights report reveals that in 2021, about 402 billion masks were sold worldwide, compared with an estimated 23 billion in 2023. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - December 9, 2023 Category: Pharmaceuticals Source Type: news

ET Impact: DCGI asks pharma cos to adhere to production quality standards
The DCGI's move comes a few days after ET reported that industrial excipients are used in manufacturing medicines and over 50 companies manufacturing cough syrups have failed quality tests. The World Health Organization (WHO) said in October last year that the deaths of dozens of children in Gambia from acute kidney injuries might be linked to contaminated cough and cold syrups made by an Indian drug manufacturer. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - December 8, 2023 Category: Pharmaceuticals Source Type: news

GSK's Augmentin is India's no.1 drug brand
Research firm PharmaTrac data shows Augmentin sales at Rs 801 crore from November 2022-23. For the month of November, Augmentin sales stood at Rs 75 crore. It has shown a moving annual total (MAT) growth growth of 12.3%. As per the data, Glycomet GP sales stood at Rs 774 crore from same period and the sales for November stood at Rs 64 crore. It has shown a MAT growth of 7.5%. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - December 8, 2023 Category: Pharmaceuticals Source Type: news